Since cellular PDCD4 levels are in part regulated by phosphorylation-dependent proteasomal degradation in response to tumor promoters [10,11,12], stabilizing PDCD4 provides an attractive potential therapeutic target. Here, PDCD4 is linked to neoplasm.